Parlodel

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Bromocriptine mesylate

Available from:

Novartis Pharmaceuticals Australia Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

PARLODEL
®

_bromocriptine mesylate_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Parlodel.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
The information in this leaflet was
last updated on the date listed on the
final page. More recent information
on the medicine may be available.
YOU SHOULD ENSURE THAT YOU SPEAK
TO YOUR PHARMACIST OR DOCTOR TO
OBTAIN THE MOST UP TO DATE
INFORMATION ON THE MEDICINE. YOU
CAN ALSO DOWNLOAD THE MOST UP TO
DATE LEAFLET FROM
WWW.NOVARTIS.COM.AU.
Those updates may contain important
information about the medicine and
its use of which you should be aware.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Parlodel
against the benefits they expect it
will provide.
IF YOU HAVE ANY CONCERNS ABOUT THIS
MEDICINE, ASK YOUR DOCTOR OR
PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT PARLODEL IS USED
FOR
Parlodel has several uses. It can be
used for the following medical
conditions:
1. Prevention/suppression of breast
milk production (lactation) in
women who cannot/do not breast-
feed for medical reasons. If breast
milk production has already
begun, your doctor can advise
you about other methods of
stopping lactation.
2. Treatment of people who have
high blood levels of a hormone
called prolactin. This condition is
sometimes caused by a type of
tumour called a prolactinoma.
3. Treatment of acromegaly, a
disease in which the body
produces too much growth
hormone. Parlodel treats this
disease by reducing the level of
growth hormone in the blood.
4. To relieve symptoms, such as
shaking of the limbs, stiffness and
slowness of movement, in people
with Parkinson's disease. Parlodel
is often used in combination with
other medicines such as levodopa.
Parlodel contains the active
ingredient, bromocriptine. It belongs
to a group of medicines known as the
ergot alkaloids, derived from a

Summary of Product characteristics

1 
PARLODEL
®

(BROMOCRIPTINE MESYLATE) 

NAME OF THE MEDICINE 

Active ingredient:    Bromocriptine mesylate 
Chemical names:     Ergotaman-3’,6’,18-trione,
2-bromo-12’-hydroxy-2’-(1-methylethyl)-5’-  
                                (2-methylpropyl)-,
(5’α)-; 

   2-Bromoergocryptine monomethanesulphonate;  
                                 2-bromo-

- ergocryptine mesylate;  

CAS Number:          22260-51-1 
Chemical structure:  
H
CH3
H
H
HN
N
Br
O
O
N
OH
H
CH
2
CH(CH
3
)
2
O
N
H
N
C
O
CH(CH
3
)
2

Chemical Formula: C
32
H
40
BrN
5
O
5
CH
4
O
3
S 
Molecular weight:   750.7 (mesylate salt); 654.5 (free base) 

DESCRIPTION 

Bromocriptine  mesylate  is  a  peptide  ergot  alkaloid,  poorly  soluble  in  water  (<0.1%  at 
20 - 25
0
C). Freely soluble in methanol. Solubility in ethanol (70% v/v) is 75%.  

Parlodel tablets and capsules contain bromocriptine mesylate.   
EXCIPIENTS 
Tablets: magnesium stearate, silica colloidal anhydrous, maize starch, disodium edetate, maleic 
acid, and lactose.  

Capsules: magnesium stearate, silica colloidal anhydrous, maize starch,  maleic  acid,  lactose, 
gelatin, and titanium dioxide. The 5 mg capsules also contain shellac, red iron oxide CI77491, 
and indigo carmine CI73015.  

2 

PHARMACOLOGY 

Parlodel has a pharmacological spectrum unlike that of most
classical ergot compounds, having 
no uterotonic and little vasoconstrictor activity.  Its principal effects derive from dopaminergic 
receptor  stimulant  activity.    It  inhibits  prolactin  secretion  and  the  effect  can  be  demonstrated 
after  single  or  repeated  oral  administration  of  the